Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & Administrative
Others
Ratios

Bluejay Diagnostics (BJDX) Research & Development (2022 - 2023)

Bluejay Diagnostics (BJDX) has disclosed Research & Development for 2 consecutive years, with $1.3 million as the latest value for Q4 2023.

  • Quarterly Research & Development fell 2.65% to $1.3 million in Q4 2023 from the year-ago period, while the trailing twelve-month figure was $5.7 million through Dec 2023, up 37.63% year-over-year, with the annual reading at $3.0 million for FY2025, 12.25% down from the prior year.
  • Research & Development hit $1.3 million in Q4 2023 for Bluejay Diagnostics, down from $1.4 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $1.7 million in Q2 2023 to a low of $694757.0 in Q1 2022.